Emergent resumes production of Johnson & Johnson’s Covid vaccine
The Peninsula
The U.S. Food and Drug Administration cleared Johnson & Johnson’s Covid-19 vaccine manufacturer Emergent BioSolutions Inc. to resume production of the shot after a series of mishaps that led it to halt manufacturing.
The Gaithersburg, Maryland-based contract manufacturer said in statement on Thursday that U.S. regulators decided to allow it to resume manufacturing after completing extensive reviews at its facility in Baltimore’s Bayview neighborhood. A Biden administration official said that the FDA decided to allow Emergent to resume production after visiting the facility earlier this week.More Related News